浦银国际发表报告指，再鼎医药(09688.HK) 第三季净亏损显著收窄，好于预期。 产品收入为1.018亿美元，符合市场和该行预期。净亏损为4,167万美元，好于市场和该行预期，主要由于销售行政费用低于预期。
报告指，管理层维持此前艾加莫德用药时长为1年5个 周期的预测。剂型扩展方面，皮下剂型用于MG和CIDP适应症均已于下半年获批，预计将于第四季推向市场，预充针剂型有望于明年申请上市。
浦银国际维持再鼎医药“买入”评级，略微下调美股及港股目标价各至55美元及43港元，维持“买入”评级。基于更新的财务信息，将全年净亏损预测缩窄至2.6亿美元， 以及微调明年净亏损预测、后年净利润预测。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-14 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.